Free Trial

Biomea Fusion (BMEA) Stock Price, News & Analysis

+0.65 (+5.91%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
731,482 shs
Average Volume
919,184 shs
Market Capitalization
$418.70 million
P/E Ratio
Dividend Yield
Price Target

Biomea Fusion MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
357.1% Upside
$53.25 Price Target
Short Interest
47.23% of Float Sold Short
Dividend Strength
News Sentiment
1.46mentions of Biomea Fusion in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($4.20) to ($3.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars

Medical Sector

678th out of 931 stocks

Pharmaceutical Preparations Industry

314th out of 426 stocks

BMEA stock logo

About Biomea Fusion Stock (NASDAQ:BMEA)

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

BMEA Stock Price History

BMEA Stock News Headlines

Recap: Biomea Fusion Q4 Earnings
BMEA Apr 2024 5.000 put
BMEA Apr 2024 5.000 call
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
Wall Street Expects 190% Upside for This Biotech Stock
See More Headlines
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.74 per share


Free Float
Market Cap
$418.70 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

BMEA Stock Analysis - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares.
View BMEA analyst ratings
or view top-rated stocks.

What is Biomea Fusion's stock price target for 2024?

7 Wall Street analysts have issued 1-year target prices for Biomea Fusion's shares. Their BMEA share price targets range from $15.00 to $90.00. On average, they anticipate the company's share price to reach $53.25 in the next twelve months. This suggests a possible upside of 357.1% from the stock's current price.
View analysts price targets for BMEA
or view top-rated stocks among Wall Street analysts.

How have BMEA shares performed in 2024?

Biomea Fusion's stock was trading at $14.52 at the beginning of the year. Since then, BMEA stock has decreased by 19.8% and is now trading at $11.65.
View the best growth stocks for 2024 here

Are investors shorting Biomea Fusion?

Biomea Fusion saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 13,140,000 shares, a decrease of 5.9% from the April 30th total of 13,970,000 shares. Based on an average daily trading volume, of 990,500 shares, the days-to-cover ratio is currently 13.3 days. Currently, 47.2% of the shares of the stock are short sold.
View Biomea Fusion's Short Interest

When is Biomea Fusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our BMEA earnings forecast

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) released its quarterly earnings data on Thursday, May, 2nd. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by $0.07.

When did Biomea Fusion IPO?

Biomea Fusion (BMEA) raised $120 million in an IPO on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Janus Henderson Group PLC (3.58%), Price T Rowe Associates Inc. MD (0.49%), Ikarian Capital LLC (0.00%), Simplex Trading LLC (0.00%) and Griffin Asset Management Inc. (0.11%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMEA) was last updated on 5/29/2024 by Staff

From Our Partners